The SABCS 2021: Updates in HER2+ Breast Cancer publication provides expert insights on clinical news in HER2-positive breast cancer treatment from the 2021 San Antonio Breast Cancer Symposium.
Funding From Daiichi Sankyo/Content Developed Independently by OncLive
January 31, 2022
Article
Sara A. Hurvitz, MD, provides perspective on key research that was presented during the 2021 SABCS in HER2-positive metastatic breast cancer.
January 19, 2022
Video
John Cole, MD, discusses the next steps with tucatinib in HER2-positive breast cancer.
January 14, 2022
Video
Joanne Mortimer, MD, discusses the potential benefit of tucatinib plus antibody-drug conjugates in HER2-positive breast cancer.
January 14, 2022
Video
Sara A. Hurvitz, MD, discusses the clinical implications of the ongoing phase 2 SUMMIT trial in HER2-mutated breast cancer.
December 14, 2021
Video
Sara A. Hurvitz, MD, discusses the clinical implications of the phase 3 DESTINY-Breast03 trial in HER2-positive breast cancer.
December 14, 2021
Video
Aileen I. Fernandez, PhD, discusses the need to refine immunohistochemistry testing in HER2-positive breast cancer.